A REVIEW ON ASPECTS OF CURRENT PHARMACOTHERAPIES FOR COVID-19

Abstract

The novel coronavirus has infected over 609,848,852 individuals throughout the
world with a total death of over 6.5 million since its outbreak in December 2019. Since then many
therapeutic options have been approached and tested in clinical trials as well to find a potential cure or
preventive therapy for the COVID-19 disease. This review summarizes the potential therapeutic
options currently available for the treatment of COVID-19 including lopinavir-ritonavir,
Hydroxychloroquine, Remdesivir, Ribavirin, dexamethasone, interferon, antibodies, Tocilizumab,
Azithromycin, Piperacillin-tazobactam, Moxifloxacin, Ivermectin, Nitazoxanide, Baricitinib, and
Arbidol. This study briefly discusses the clinical trials and encompasses the dosage, efficacy, adverse
drug reactions, and possible mechanism of action of the potential treatment candidate where
applicable. The growing number of reported cases posits an exigent need for a suitable therapy for the
prevention and cure of this disease. Therefore, the study aims to provide vital information on each drug
to highlight the latest scientific research that could be helpful for better prevention/treatment of
COVID-19 disease.